|
ARRY-797 is an oral, selective p38 mitogen-activated protein kinase inhibitor. ARRY-797 is being studied in a Phase 3 trial in patients with lamin A/C-related dilated cardiomyopathy (LMNA-related DCM), a rare, degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis.
According to reaxys, the correct CAS should be “1034189-82-6", please check the correct link. Contact：Wuhan Sun-shine Bio-technologyCorporation Limited Add: Building C16, No.388 Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790
Web: http://www.sun-shinechem.com
| 
_1036404-17-7.png)